Díaz-Villamarín, X.; Nieto-Sánchez, M.T.; Martínez-Pérez, M.; Novo-González, P.; Fernández-Varón, E.; Torres-García, A.; González Astorga, B.; Blancas, I.; Cabeza-Barrera, J.; Morón, R.
Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review. Pharmaceutics 2025, 17, 542.
https://doi.org/10.3390/pharmaceutics17050542
AMA Style
Díaz-Villamarín X, Nieto-Sánchez MT, Martínez-Pérez M, Novo-González P, Fernández-Varón E, Torres-García A, González Astorga B, Blancas I, Cabeza-Barrera J, Morón R.
Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review. Pharmaceutics. 2025; 17(5):542.
https://doi.org/10.3390/pharmaceutics17050542
Chicago/Turabian Style
Díaz-Villamarín, Xando, María Teresa Nieto-Sánchez, María Martínez-Pérez, Paula Novo-González, Emilio Fernández-Varón, Alicia Torres-García, Beatriz González Astorga, Isabel Blancas, José Cabeza-Barrera, and Rocío Morón.
2025. "Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review" Pharmaceutics 17, no. 5: 542.
https://doi.org/10.3390/pharmaceutics17050542
APA Style
Díaz-Villamarín, X., Nieto-Sánchez, M. T., Martínez-Pérez, M., Novo-González, P., Fernández-Varón, E., Torres-García, A., González Astorga, B., Blancas, I., Cabeza-Barrera, J., & Morón, R.
(2025). Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review. Pharmaceutics, 17(5), 542.
https://doi.org/10.3390/pharmaceutics17050542
